Indivior Pharmaceuticals, Inc. (INDV)
NASDAQ · Healthcare
Indivior Pharmaceuticals, Inc. EBITDA 2022–2025
Indivior Pharmaceuticals, Inc. annual/quarterly ebitda history and growth rate from 2022 to 2026. EBITDA stands for Earnings Before Interest, Taxes, Depreciation and Amortization. It is widely used as a measure of core operational profitability.
- Indivior Pharmaceuticals, Inc. ebitda for the quarter ending March 31, 2026 was 139.0 M, a 101.45% increase year-over-year.
- Indivior Pharmaceuticals, Inc. annual ebitda for 2025 was 272.0 M, a 403.70% increase from 2024.
- Indivior Pharmaceuticals, Inc. annual ebitda for 2024 was 54.0 M, a 139.42% decrease from 2023.
- Indivior Pharmaceuticals, Inc. annual ebitda for 2023 was -137.0 M, a 110.77% increase from 2022.
- Indivior Pharmaceuticals, Inc. annual ebitda for 2022 was -65.0 M.
EBITDA
QUARTERLY · $B
Indivior Pharmaceuticals, Inc. EBITDA — FAQ
Indivior Pharmaceuticals, Inc. (INDV) ebitda over the last 4 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see INDV's ebitda history?
The chart and table above show Indivior Pharmaceuticals, Inc.'s ebitda by year and by quarter, including the growth rate.